lisaftoclax
3 abstracts
Abstract
Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.Org: Ascentage Pharma Group, Inc.,
Abstract
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Ascentage Pharma Pty Ltd.,
Abstract
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group, Jiangsu Ascentage Pharma Pty Ltd.,